Leo Pharma’s Timber bet falls flat following Phase III failure
A year after hedging its bets on Timber Pharmaceuticals’ dermatology pipeline, Leo Pharma has reported a Phase III failure for…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a trainee reporter for Medical Device Network, covering developments in the healthcare sector. Coming from a scientific and medical background, Robert has reported across various topics with expertise in neuroscience, genetics, and epidemiology. Previously, he worked on a freelance basis with New Scientist.
-
-
FDA declines to approve Regeneron’s linvoseltamab amid manufacturing issues
The US Food and Drug Administration (FDA) has declined to approve Regeneron Pharmaceuticals’ multiple myeloma candidate linvoseltamab following an issue…
-
Emergent joins mpox fight with 50,000 vaccine dose donation to Africa
Emergent BioSolutions said it would donate 50,000 doses of its smallpox vaccine to the Democratic Republic of the Congo (DRC)…
-
US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan
Immuron Limited has won an A$3.5m ($2.3m) grant to develop a version of its anti-diarrhoeal medication Travelan, following support from…
-
Bavarian Nordic seeks authorisation for mpox vaccine’s use in adolescents
Amid the ongoing global mpox public health emergency, Bavarian Nordic – manufacturer of the only approved vaccine for the disease…
-
Arrowhead announces push into obesity space with two gene therapies
A month after axing a Phase II cardiovascular candidate, Arrowhead Pharmaceuticals has placed a bullseye target on the obesity treatment…
-
Bavarian Nordic outlays 215,000 mpox vaccine dose supply to African countries
On the same day Africa’s Centres for Disease Control and Prevention (CDC) declared a public health emergency amid mpox outbreaks…
-
US judge denies initial attempt by Novartis to block generic Entresto launch
Novartis’s bid to block the launch of a biosimilar for its best-selling drug Entresto (sacubitril/valsartan) got off to a faltering…
-
FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues
The US Food and Drug Administration (FDA) has approved Sandoz’s Enzeevu (aflibercept-abzv), the drugmaker’s biosimilar for wet age-related macular degeneration…
-
Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue
Eli Lilly has raised its revenue guidance for 2024, as weight-loss drug Zepbound (tirzepatide) propelled the drugmaker’s financial performance in…